It has brought numerous treatment options, even in the first line, from monotherapies to combinations with other ICIs, such as CTLA-4 (cytotoxic T lymphocyte antigen 4) or LAG-3 (Lymphocyte-activation gene 3) inhibitors, or with chemotherapy in NSCLC. The gene discussed is LAG3; the disease is non-small cell lung carcinoma.